
To be announced
To be announced
To be announced
To be announced
To be announced
NSE/BSE
To be announced
Symbiotec Pharmalab Ltd., incorporated in 2002, is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves both domestic and international markets across regulated as well as emerging regions. The company focuses on research-driven man
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | -- |
| Non-Institutional Investors (NIIs) | 15% | -- |
| Retail Individual Investors (RIIs) | 35% | -- |
Global leadership in corticosteroid and steroidal-hormone APIs
Strong regulatory approvals including US FDA and EU-GMP
Vertically and backward-integrated manufacturing platform
Long-standing relationships with global pharmaceutical customers
Continuous investment in R&D and innovation
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| -- | -- | -- |
| Issue Composition: | |
|---|---|
| Face Value | ₹2 per share |
| Total Issue Size | 0 shares (aggregating up to To be announced) |
| Fresh Issue | 0 shares (aggregating up to To be announced) |
| Offer for Sale | 0 shares of ₹2 (aggregating up to To be announced) |
| Issue Type | Book building IPO |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 34.47 shares |
| Post-Issue Shareholding | 0 shares |
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Symbiotec Pharmalab ipo has been designed to ensure broad participation while maintaining optimal price discovery.
385 / 2 Pigdamber Near Mashal Hotel Indore
MUFG Intime India Pvt.Ltd.
| Book Running Lead Manager(s) |
|---|
| JM Financial Ltd. | Avendus Capital Pvt.Ltd. | Motilal Oswal Investment Advisors Ltd. |